EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 89bio's Enterprise Value is $334.78 Mil.
89bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-133.53 Mil. Therefore, 89bio's EV-to-EBIT for today is -2.51.
The historical rank and industry rank for 89bio's EV-to-EBIT or its related term are showing as below:
ETNB'
s EV-to-EBIT Range Over the Past 10 Years
Min: -11.54 Med: 0 Max: 1.13
Current: -2.51
During the past 6 years, the highest EV-to-EBIT of 89bio was 1.13. The lowest was -11.54. And the median was 0.00.
ETNB's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.325
vs ETNB: -2.51
The historical data trend for 89bio's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, 89bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
89bio EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, 89bio's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where 89bio's EV-to-EBIT falls into.
89bio's current Enterprise Value is $334.78 Mil.
89bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio (NAS:ETNB) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
89bio's Enterprise Value for the quarter that ended in Dec. 2023 was $490.06 Mil.
89bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-133.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
89bio EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of 89bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ETNB has been successfully added to your 